T. Rowe Price Investment Management’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10K | Sell |
7,299
-4,881,313
| -100% | -$6.69M | ﹤0.01% | 676 |
|
|
2025
Q1 | $5.77M | Sell |
4,888,612
-8,232
| -0.2% | -$9.72K | ﹤0.01% | 583 |
|
|
2024
Q4 | $8.96M | Buy |
+4,896,844
| New | +$8.96M | 0.01% | 558 |
|
|
2024
Q2 | – | Sell |
-8,397,820
| Closed | -$31.5M | – | 648 |
|
|
2024
Q1 | $31.5M | Buy |
8,397,820
+644,039
| +8% | +$2.42M | 0.02% | 457 |
|
|
2023
Q4 | $76.1M | Buy |
7,753,781
+338,257
| +5% | +$3.32M | 0.05% | 320 |
|
|
2023
Q3 | $61.9M | Buy |
7,415,524
+1,243,925
| +20% | +$10.4M | 0.04% | 335 |
|
|
2023
Q2 | $82.1M | Buy |
6,171,599
+751,036
| +14% | +$9.99M | 0.06% | 293 |
|
|
2023
Q1 | $62.8M | Sell |
5,420,563
-649,976
| -11% | -$7.53M | 0.05% | 334 |
|
|
2022
Q4 | $49.7M | Sell |
6,070,539
-1,502,019
| -20% | -$12.3M | 0.04% | 356 |
|
|
2022
Q3 | $44M | Buy |
+7,572,558
| New | +$44M | 0.04% | 362 |
|